Zura Bio Ltd. to be Acquired by 03 Life Sciences

TL;DR

Zura Bio getting bought by 03 Life Sciences, deal expected Q1 2025.

AI Summary

Zura Bio Ltd. announced on October 23, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the first quarter of 2025. Zura Bio Ltd. was formerly known as JATT Acquisition Corp.

Why It Matters

This acquisition signifies a strategic move within the biotechnology sector, potentially impacting Zura Bio's pipeline and future development under new ownership.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, and the success of the integration and future development of Zura Bio's assets under 03 Life Sciences remains to be seen.

Key Players & Entities

• Zura Bio Ltd (company) — Registrant
• 03 Life Sciences (company) — Acquiring entity
• JATT Acquisition Corp (company) — Former name of Zura Bio Ltd
• October 23, 2024 (date) — Date of earliest event reported
• First quarter of 2025 (date) — Expected closing date of the acquisition

FAQ

Key Financial Figures

• $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar

Filing Documents

• tm2427003d1_8k.htm (8-K) — 40KB
• 0001104659-24-112240.txt ( ) — 213KB
• zura-20241023.xsd (EX-101.SCH) — 3KB
• zura-20241023_lab.xml (EX-101.LAB) — 33KB
• zura-20241023_pre.xml (EX-101.PRE) — 22KB
• tm2427003d1_8k_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On October 23, 2024, Zura Bio Limited (the "Company") held its Annual General Meeting of Shareholders (the "Annual Meeting"), at which a quorum was present. At the Annual Meeting, the shareholders of the Company voted on the following three proposals: (1) the election, by ordinary resolution, of the nine (9) directors listed below (the "Director Nominees") to the Company's Board of Directors (the "Board") to hold office until the 2025 annual general meeting of shareholders or until their respective successors have been elected and qualified, or until their earlier death, resignation or removal ("Proposal 1"); (2) the ratification, by ordinary resolution, of the re-appointment by the Audit Committee of the Board of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal 2"); and (3) the approval, by ordinary resolution, of the adjournment of the Annual Meeting by the chairman thereof to a later date or dates, if necessary, for the purpose of soliciting additional proxies in favor of the foregoing proposals, in the event the Company does not receive the requisite shareholder votes to approve the foregoing proposals ("Proposal 3"). Each of these proposals is described in greater detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 13, 2024. The final results of the voting on each proposal are set forth below. Proposal 1 - Election of Directors. The Company's shareholders elected the Director Nominees as directors of the Company, each to hold office until the 2025 annual general meeting of shareholders or until their respective successors have been elected and qualified, or until their earlier death, resignation or removal. The votes cast were as follows: Nominee For Against Abstain Broker Non-Votes Neil Graham 39,323,084 17,763 6,043

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 29, 2024 ZURA BIO LIMITED By: /s/ Kim Davis Kim Davis Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR